- Home
- SEER vs ATOS Comparison
SEER vs ATOS Comparison
Compare SEER & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | ATOS |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 100.8M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SEER | ATOS |
|---|---|---|
| Price | $1.91 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 198.9K | ★ 1.6M |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,376,999.00 | N/A |
| Revenue This Year | $22.37 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $1.62 | $0.55 |
| 52 Week High | $2.45 | $1.29 |
Technical Indicators
Market Signals| Indicator | SEER | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 40.50 |
| Support Level | $1.82 | $0.55 |
| Resistance Level | $1.94 | $0.70 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 82.35 | 46.41 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.